Skip to main content
PMC home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2020 Jan;24(3):1–164. doi: 10.3310/hta24030

Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation.

Rui Duarte, Angela Stainthorpe, Janette Greenhalgh, Marty Richardson, Sarah Nevitt, James Mahon, Eleanor Kotas, Angela Boland, Howard Thom, Tom Marshall, Mark Hall, Yemisi Takwoingi
PMCID: PMC6983912  PMID: 31933471

Abstract

BACKGROUND

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and is associated with an increased risk of stroke and congestive heart failure. Lead-I electrocardiogram (ECG) devices are handheld instruments that can be used to detect AF at a single time point in people who present with relevant signs or symptoms.

OBJECTIVE

To assess the diagnostic test accuracy, clinical impact and cost-effectiveness of using single time point lead-I ECG devices for the detection of AF in people presenting to primary care with relevant signs or symptoms, and who have an irregular pulse compared with using manual pulse palpation (MPP) followed by a 12-lead ECG in primary or secondary care.

DATA SOURCES

MEDLINE, MEDLINE Epub Ahead of Print and MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, PubMed, Cochrane Databases of Systematic Reviews, Cochrane Central Database of Controlled Trials, Database of Abstracts of Reviews of Effects and the Health Technology Assessment Database.

METHODS

The systematic review methods followed published guidance. Two reviewers screened the search results (database inception to April 2018), extracted data and assessed the quality of the included studies. Summary estimates of diagnostic accuracy were calculated using bivariate models. An economic model consisting of a decision tree and two cohort Markov models was developed to evaluate the cost-effectiveness of lead-I ECG devices.

RESULTS

No studies were identified that evaluated the use of lead-I ECG devices for patients with signs or symptoms of AF. Therefore, the diagnostic accuracy and clinical impact results presented are derived from an asymptomatic population (used as a proxy for people with signs or symptoms of AF). The summary sensitivity of lead-I ECG devices was 93.9% [95% confidence interval (CI) 86.2% to 97.4%] and summary specificity was 96.5% (95% CI 90.4% to 98.8%). One study reported limited clinical outcome data. Acceptability of lead-I ECG devices was reported in four studies, with generally positive views. The de novo economic model yielded incremental cost-effectiveness ratios (ICERs) per quality-adjusted life-year (QALY) gained. The results of the pairwise analysis show that all lead-I ECG devices generated ICERs per QALY gained below the £20,000-30,000 threshold. Kardia Mobile (AliveCor Ltd, Mountain View, CA, USA) is the most cost-effective option in a full incremental analysis.

LIMITATIONS

No published data evaluating the diagnostic accuracy, clinical impact or cost-effectiveness of lead-I ECG devices for the population of interest are available.

CONCLUSIONS

Single time point lead-I ECG devices for the detection of AF in people with signs or symptoms of AF and an irregular pulse appear to be a cost-effective use of NHS resources compared with MPP followed by a 12-lead ECG in primary or secondary care, given the assumptions used in the base-case model.

FUTURE WORK

Studies assessing how the use of lead-I ECG devices in this population affects the number of people diagnosed with AF when compared with current practice would be useful.

STUDY REGISTRATION

This study is registered as PROSPERO CRD42018090375.

FUNDING

The National Institute for Health Research Health Technology Assessment programme.

Plain language summary

Atrial fibrillation (AF) is the most common type of abnormal heart rhythm. People with AF are more likely to have a serious stroke or die than people without the condition. Many people go to their general practitioner (GP) with the signs or symptoms commonly linked to AF, such as feeling dizzy, being short of breath, feeling tired and having heart palpitations. GPs check for AF by taking the patient’s pulse by hand. If the GP thinks that the patient might have AF, a 12-lead electrocardiogram (ECG) test is arranged. Lead-I (i.e. one lead) ECGs are handheld electronic devices that could detect AF more accurately than a manual pulse check. If GPs were to routinely use lead-I ECG devices, people with suspected AF could receive treatment while waiting for the AF diagnosis to be confirmed by a 12-lead ECG. This study aimed to assess whether or not the use of lead-I ECGs in GP surgeries could benefit these patients and offer good value for money to the NHS. All studies that examined how well lead-I ECGs identified people with AF were reviewed, and the economic value of using these devices was assessed. No evidence was found that examined the use of lead-I ECGs for people with signs or symptoms of AF. As an alternative, evidence for the use of lead-I ECGs for people with no symptoms of AF was searched for and these data were used to assess value for money. The study found that using a manual pulse check followed by a lead-I ECG offers value for money when compared with a manual pulse check followed by a 12-lead ECG. This is mostly because patients with AF can begin treatment earlier when a GP has access to a lead-I ECG device.

Full text of this article can be found in Bookshelf.

References

  1. National Institute for Health and Care Excellence. Clinical Knowledge Summaries: Atrial Fibrillation. London: NICE; 2015. URL: https://cks.nice.org.uk/atrial-fibrillation#!topicsummary (accessed January 2018).
  2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–962. https://doi.org/10.1093/eurheartj/ehw210 doi: 10.1093/eurheartj/ehw210. [DOI] [PubMed]
  3. National Institute for Health and Care Excellence. Atrial Fibrillation: Management. Clinical Guideline CG180. London: NICE; 2014. URL: www.nice.org.uk/guidance/cg180/chapter/Introduction (accessed January 2018). [PubMed]
  4. Dewland TA, Olgin JE, Vittinghoff E, Marcus GM. Incident atrial fibrillation among Asians, Hispanics, blacks, and whites. Circulation 2013;128:2470–7. https://doi.org/10.1161/CIRCULATIONAHA.113.002449 doi: 10.1161/CIRCULATIONAHA.113.002449. [DOI] [PubMed]
  5. Bai Y, Wang YL, Shantsila A, Lip GYH. The global burden of atrial fibrillation and stroke: a systematic review of the clinical epidemiology of atrial fibrillation in Asia. Chest 2017;152:810–20. https://doi.org/10.1016/j.chest.2017.03.048 doi: 10.1016/j.chest.2017.03.048. [DOI] [PubMed]
  6. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, Folsom AR. Incidence of atrial fibrillation in whites and African–Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2009;158:111–17. https://doi.org/10.1016/j.ahj.2009.05.010 doi: 10.1016/j.ahj.2009.05.010. [DOI] [PMC free article] [PubMed]
  7. Lane DA, Skjøth F, Lip GYH, Larsen TB, Kotecha D. Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. J Am Heart Assoc 2017;6:e005155. https://doi.org/10.1161/JAHA.116.005155 doi: 10.1161/JAHA.116.005155. [DOI] [PMC free article] [PubMed]
  8. NHS Digital. Quality and Outcomes Framework (QOF) – 2015–16. Leeds: NHS Digital; 2016. URL: https://digital.nhs.uk/data-and-information/publications/statistical/quality-and-outcomes-framework-achievement-prevalence-and-exceptions-data/quality-and-outcomes-framework-qof-2015-16 (accessed January 2018).
  9. National Institute for Health and Care Excellence. Lead-I Electrocardiogram (ECG) Devices for Detecting Atrial Fibrillation Using Single-Time Point Testing in Primary Care: Final Scope. London: NICE; 2018. URL: www.nice.org.uk/guidance/gid-dg10018/documents/final-scope (accessed March 2018).
  10. Public Health England. Atrial Fibrillation Prevalence Estimates in England: Application of Recent Population Estimates of AF in Sweden. London: Public Health England; 2017. URL: www.gov.uk/government/uploads/system/uploads/attachment_data/file/644869/atrial_fibrillation_AF_briefing.pdf (accessed January 2018).
  11. NHS Digital. Quality and Outcomes Framework (QOF) – 2016–17. Leeds: NHS Digital; 2017. URL: https://digital.nhs.uk/catalogue/PUB30124 (accessed January 2018).
  12. Adderley NJ, Ryan R, Nirantharakumar K, Marshall T. Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016. Heart 2019;105:27–33. https://doi.org/10.1136/heartjnl-2018-312977 doi: 10.1136/heartjnl-2018-312977. [DOI] [PubMed]
  13. Lip GYH, Hee FLLS. Paroxysmal atrial fibrillation. QJM 2001;94:665–78. https://doi.org/10.1093/qjmed/94.12.665 doi: 10.1093/qjmed/94.12.665. [DOI] [PubMed]
  14. Lown M, Yue A, Lewith G, Little P, Moore M. Screening for Atrial Fibrillation using Economical and accurate TechnologY (SAFETY) – a pilot study. BMJ Open 2017;7:e013535. https://doi.org/10.1136/bmjopen-2016-013535 doi: 10.1136/bmjopen-2016-013535. [DOI] [PMC free article] [PubMed]
  15. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719–47. https://doi.org/10.1093/eurheartj/ehs253 doi: 10.1093/eurheartj/ehs253. [DOI] [PubMed]
  16. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D’Agostino RB. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760–4. https://doi.org/10.1161/01.STR.27.10.1760 doi: 10.1161/01.STR.27.10.1760. [DOI] [PubMed]
  17. Stroke Association. State of the Nation: Stroke Statistics. 2017. URL: www.stroke.org.uk/sites/default/files/state_of_the_nation_2017_final_1.pdf (accessed June 2018).
  18. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 2015;36:281–8. https://doi.org/10.1093/eurheartj/ehu307 doi: 10.1093/eurheartj/ehu307. [DOI] [PubMed]
  19. Senoo K, Lip GY, Lane DA, Büller HR, Kotecha D. Residual risk of stroke and death in anticoagulated patients according to the type of atrial fibrillation: AMADEUS Trial. Stroke 2015;46:2523–8. https://doi.org/10.1161/STROKEAHA.115.009487 doi: 10.1161/STROKEAHA.115.009487. [DOI] [PubMed]
  20. Flaker GC, Belew K, Beckman K, Vidaillet H, Kron J, Safford R, et al. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005;149:657–63. https://doi.org/10.1016/j.ahj.2004.06.032 doi: 10.1016/j.ahj.2004.06.032. [DOI] [PubMed]
  21. MDCalc. CHA2DS2-VASc Score for Atrial Fibrillation Stroke Risk. 2015. URL: www.mdcalc.com/cha2ds2-vasc-score-for-atrial-fibrillation-stroke-risk/ (accessed June 2018).
  22. MDCalc. HAS-BLED Score for Major Bleeding Risk. 2018. URL: www.mdcalc.com/has-bled-score-major-bleeding-risk (accessed January 2018).
  23. Plessey. imPULSE. 2018. URL: www.plesseysemiconductors.com/products/impulse/ (accessed January 2018).
  24. Alive Technologies. Kardia Mobile. 2018. URL: www.alivetec.com/pages/alivecor-heart-monitor (accessed January 2018).
  25. Applied Biomedical Systems BV. Mydiagnostick. 2018. URL: www.mydiagnostick.com/ (accessed January 2018).
  26. Cardiocity Ltd. RhythmPadGP. 2017. URL: www.cardiocity.com/?portfolio=rhythm-pad-gp (accessed January 2018).
  27. Zenicor Medical Systems AB. Zenicor-ECG. 2018. URL: https://zenicor.com/zenicor-ekg/ (accessed January 2018).
  28. Centre for Reviews and Dissemination. Systematic Reviews: CRD’s Guidance for Undertaking Systematic Reviews in Health Care. York: Centre for Reviews and Dissemination; 2009. URL: www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm (accessed January 2018).
  29. National Institute for Health and Care Excellence. Diagnostic Assessment Programme Manual. 2011. URL: www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-diagnostics-guidance/Diagnostics-assessment-programme-manual.pdf (accessed January 2018). [PubMed]
  30. Cochrane Methods: Screening and Diagnostic Tests. Handbook for DTA Reviews. 2009. URL: http://srdta.cochrane.org/handbook-dta-reviews (accessed January 2018).
  31. McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: the PRISMA-DTA statement. JAMA 2018;319:388–96. https://doi.org/10.1001/jama.2017.19163 doi: 10.1001/jama.2017.19163. [DOI] [PubMed]
  32. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36. https://doi.org/10.7326/0003-4819-155-8-201110180-00009 doi: 10.7326/0003-4819-155-8-201110180-00009. [DOI] [PubMed]
  33. Herzog R, Álvarez-Pasquin MJ, Díaz C, Del Barrio JL, Estrada JM, Gil Á. Are healthcare workers’ intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health 2013;13:154. https://doi.org/10.1186/1471-2458-13-154 doi: 10.1186/1471-2458-13-154. [DOI] [PMC free article] [PubMed]
  34. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa, ON: Ottawa Hospital Research Institute; 2012. URL: ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed January 2018).
  35. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. https://doi.org/10.1136/bmj.d5928 doi: 10.1136/bmj.d5928. [DOI] [PMC free article] [PubMed]
  36. CASP. Qualitative Research: Appraisal Tool. 10 Questions to Help you Make Sense of Qualitative Research. 2006. URL: www.phru.nhs.uk/Doc_Links/Qualitative_Appraisal_Tool.pdf (accessed February 2018).
  37. Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol 2006;59:1331–2. https://doi.org/10.1016/j.jclinepi.2006.06.011 doi: 10.1016/j.jclinepi.2006.06.011. [DOI] [PubMed]
  38. Desteghe L, Raymaekers Z, Lutin M, Vijgen J, Dilling-Boer D, Koopman P, et al. Performance of handheld electrocardiogram devices to detect atrial fibrillation in a cardiology and geriatric ward setting. Europace 2017;19:29–39. https://doi.org/10.1093/europace/euw025 doi: 10.1093/europace/euw025. [DOI] [PubMed]
  39. Williams J, Pearce K, Benett I. The effectiveness of a mobile ECG device in identifying AF: sensitivity, specificity and predictive value. Br J Cardiol 2015;22:70–2.
  40. Takwoingi Y, Guo B, Riley RD, Deeks JJ. Performance of methods for meta-analysis of diagnostic test accuracy with few studies or sparse data. Stat Methods Med Res 2017;26:1896–911. https://doi.org/10.1177/0962280215592269 doi: 10.1177/0962280215592269. [DOI] [PMC free article] [PubMed]
  41. Desteghe L, Raymaekers Z, Vijgen J, Dilling-Boer D, Koopman P, Schurmans J, et al. Accuracy and cost-effectiveness of two handheld electrocardiogram recorders to screen for atrial fibrillation in a hospital setting. Eur Heart J 2016;37:1265.
  42. Desteghe L, Raymaekers Z, Vijgen J, Dilling-Boer D, Koopman P, Schurmans J, et al. Accuracy and usability of handheld electrocardiogram recorders to detect atrial fibrillation in hospitalised patients. EP Europace 2016;18:i177. https://doi.org/10.1093/europace/18.suppl_1.i177c doi: 10.1093/europace/18.suppl_1.i177c. [DOI]
  43. Doliwa PS, Frykman V, Rosenqvist M. Short-term ECG for out of hospital detection of silent atrial fibrillation episodes. Scand Cardiovasc J 2009;43:163–8. https://doi.org/10.1080/14017430802593435 doi: 10.1080/14017430802593435. [DOI] [PubMed]
  44. Haberman ZC, Jahn RT, Bose R, Tun H, Shinbane JS, Doshi RN, et al. Wireless smart phone equipped ECG enables large scale screening in diverse populations. Heart Rhythm 2014;1:S312. doi: 10.1111/jce.12634. [DOI] [PubMed]
  45. Haberman ZC, Jahn RT, Bose R, Tun H, Shinbane JS, Doshi RN, et al. Wireless smartphone ECG enables large-scale screening in diverse populations. J Cardiovasc Electrophysiol 2015;26:520–6. https://doi.org/10.1111/jce.12634 doi: 10.1111/jce.12634. [DOI] [PubMed]
  46. Lau J, Lowres N, Neubeck L, Brieger DB, Sy RW, Galloway C, et al. Validation of an iphone ECG application suitable for community screening for silent atrial fibrillation: a novel way to prevent stroke. Circulation 2012;126:A16810. doi: 10.1016/j.ijcard.2013.01.220. [DOI] [PubMed]
  47. Lau JK, Lowres N, Neubeck L, Brieger DB, Sy RW, Galloway CD, et al. iPhone ECG application for community screening to detect silent atrial fibrillation: a novel technology to prevent stroke. Int J Cardiol 2013;165:193–4. https://doi.org/10.1016/j.ijcard.2013.01.220 doi: 10.1016/j.ijcard.2013.01.220. [DOI] [PubMed]
  48. Tieleman RG, Plantinga Y, Rinkes D, Bartels GL, Posma JL, Cator R, et al. Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. Europace 2014;16:1291–5. https://doi.org/10.1093/europace/euu057 doi: 10.1093/europace/euu057. [DOI] [PMC free article] [PubMed]
  49. Vaes B, Stalpaert S, Tavernier K, Thaels B, Lapeire D, Mullens W, Degryse J. The diagnostic accuracy of the MyDiagnostick to detect atrial fibrillation in primary care. BMC Fam Pract 2014;15:113. https://doi.org/10.1186/1471-2296-15-113 doi: 10.1186/1471-2296-15-113. [DOI] [PMC free article] [PubMed]
  50. Crockford CJ, Ahmed O, Kaba R, Berry R. An analysis of the applicability of lead1 screening for cardiac arrhythmia in primary care settings using novel sensing technology & multiple commercial algorithms for automating detection to increase PPV of referrals for further investigation. Europace 2013;15:iv20.
  51. Koltowski L, Balsam P, Glowczynska R, Peller M, Maksym J, Blicharz L, et al. Comparison of Kardia Mobile (one lead ECGs records) with 12-lead ECGs in 100 consecutive patients with various cardiovascular disorders. Europace 2017;19:iii353. https://doi.org/10.1093/ehjci/eux158.263 doi: 10.1093/ehjci/eux158.263. [DOI]
  52. Battipaglia I, Gilbert K, Hogarth AJ, Tayebjee MH. Screening for atrial fibrillation in the community using a novel ECG recorder. J Atr Fibrillation 2016;9:1433. https://doi.org/10.4022/jafib.1433 doi: 10.4022/jafib.1433. [DOI] [PMC free article] [PubMed]
  53. Orchard J, Freedman SB, Lowres N, Peiris D, Neubeck L. iPhone ECG screening by practice nurses and receptionists for atrial fibrillation in general practice: the GP-SEARCH qualitative pilot study. Aust Fam Physician 2014;43:315–19. [PubMed]
  54. Chan LL, Chan SC, Yan BP. Feasibility and acceptability of atrial fibrillation screening using a hand-held ECG device in general practice setting in Hong Kong. Value in Health 2017;20:A599. https://doi.org/10.1016/j.jval.2017.08.1136 doi: 10.1016/j.jval.2017.08.1136. [DOI]
  55. Chan NY, Choy CC. Community screening for atrial fibrillation in a Chinese population using a smartphone-based wireless single-lead ECG. J Am Coll Cardiol 2015;65:A467. https://doi.org/10.1016/S0735-1097(15)60467-3 doi: 10.1016/S0735-1097(15)60467-3. [DOI]
  56. Chan NY, Choy CC. Screening for atrial fibrillation in 13 122 Hong Kong citizens with smartphone electrocardiogram. Heart 2017;103:24–31. https://doi.org/10.1136/heartjnl-2016-309993 doi: 10.1136/heartjnl-2016-309993. [DOI] [PubMed]
  57. Chan PH, Wong CK, Poh YC, Pun L, Leung WW, Wong YF, et al. Diagnostic performance of a smartphone-based photoplethysmographic application for atrial fibrillation screening in a primary care setting. J Am Heart Assoc 2016;5:e003428. https://doi.org/10.1161/JAHA.116.003428 doi: 10.1161/JAHA.116.003428. [DOI] [PMC free article] [PubMed]
  58. Gibson J, Hanjari M, Chauhan U, Watkins C. Opportunistic Detection of Atrial Fibrillation in Primary Care: A Mixed Methods Evaluation of the Introduction of New Healthcare Technology. In proceedings of the 3rd European Stroke Organisation Conference, 16–18 May 2017, Prague, Czechia.
  59. Hussain W, Thakrar D. The use of a handheld device in identifying atrial fibrillation patients during flu vaccination clinics. Europace 2016;18:ii19.
  60. Kaasenbrood F, Hollander M, Rutten FH, Gerhards LJ, Hoes AW, Tieleman RG. Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination. Europace 2016;18:1514–20. https://doi.org/10.1093/europace/euv426 doi: 10.1093/europace/euv426. [DOI] [PMC free article] [PubMed]
  61. Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 2014;111:1167–76. https://doi.org/10.1160/TH14-03-0231 doi: 10.1160/TH14-03-0231. [DOI] [PubMed]
  62. Orchard J, Lowres N, Freedman SB, Ladak L, Lee W, Zwar N, et al. Screening for atrial fibrillation during influenza vaccinations by primary care nurses using a smartphone electrocardiograph (iECG): a feasibility study. Eur J Prev Cardiol 2016;23:13–20. https://doi.org/10.1177/2047487316670255 doi: 10.1177/2047487316670255. [DOI] [PubMed]
  63. Reeves B. Preliminary evaluation of the viewing function of the imPulse ECG monitor.
  64. Waring O, Davidson NCD, Stout MS, Pearce KP. Detection of atrial fibrillation in community locations using novel technology’s as a method of stroke prevention in the over 65’s asymptomatic population – should it become standard practise? Europace 2016;18:ii39.
  65. Yan BPY, Chan LLY, Lee VWY, Freedman B. Medical Outpatient Clinics an Ideal Setting for Atrial Fibrillation Screening using a Handheld Single-Lead ECG with Automated Diagnosis. In proceedings of ESC Congress 2016, 27–31 August 2016, Fiera di Roma, Italy, P4479.
  66. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLOS Med 2009;6:e1000097. https://doi.org/10.1371/journal.pmed.1000097 doi: 10.1371/journal.pmed.1000097. [DOI] [PMC free article] [PubMed]
  67. Duarte R, Stainthorpe A, Mahon J, Greenhalgh J, Richardson M, Nevitt S, et al. Lead-I ECG for detecting atrial fibrillation in patients attending primary care with an irregular pulse using single-time point testing: a systematic review and economic evaluation. PLOS ONE 2019;14:e0226671. https://doi.org/10.1371/journal.pone.0226671 doi: 10.1371/journal.pone.0226671. [DOI] [PMC free article] [PubMed]
  68. Duarte R, Stainthorpe A, Greenhalgh J, Richardson M, Marshall T, Hall M, et al. The clinical and cost effectiveness of lead-I electrocardiogram (ECG) devices for detecting atrial fibrillation using single-time point testing in primary care. PROSPERO 2018 :CRD42018090375. URL: www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018090375
  69. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275–83. https://doi.org/10.1136/bmj.313.7052.275 doi: 10.1136/bmj.313.7052.275. [DOI] [PMC free article] [PubMed]
  70. Leeflang MM, Rutjes AW, Reitsma JB, Hooft L, Bossuyt PM. Variation of a test’s sensitivity and specificity with disease prevalence. CMAJ 2013;185:E537–44. https://doi.org/10.1503/cmaj.121286 doi: 10.1503/cmaj.121286. [DOI] [PMC free article] [PubMed]
  71. National Institute for Health and Care Excellence (NICE). NICE Clinical Knowledge Summary. Palpitations, Scenario: Current Palpitations. 2015. URL: https://cks.nice.org.uk/palpitations#!scenario (accessed June 2018).
  72. Office for National Statistics. National Life Tables: United Kingdom. 2017. URL: www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables (accessed 06 July 2018).
  73. Piccini JP, Simon DN, Steinberg BA, Thomas L, Allen LA, Fonarow GC, et al. Differences in clinical and functional outcomes of atrial fibrillation in women and men: two-year results from the ORBIT-AF Registry. JAMA Cardiol 2016;1:282–91. https://doi.org/10.1001/jamacardio.2016.0529 doi: 10.1001/jamacardio.2016.0529. [DOI] [PubMed]
  74. Welton NJ, McAleenan A, Thom HH, Davies P, Hollingworth W, Higgins JP, et al. Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis. Health Technol Assess 2017;21(29). https://doi.org/10.3310/hta21290 doi: 10.3310/hta21290. [DOI] [PubMed]
  75. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation 2013;127:930–7. https://doi.org/10.1161/CIRCULATIONAHA.112.126656 doi: 10.1161/CIRCULATIONAHA.112.126656. [DOI] [PubMed]
  76. Aronsson M, Svennberg E, Rosenqvist M, Engdahl J, Al-Khalili F, Friberg L, et al. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. Europace 2015;17:1023–9. https://doi.org/10.1093/europace/euv083 doi: 10.1093/europace/euv083. [DOI] [PubMed]
  77. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass screening for untreated atrial fibrillation: The STROKESTOP Study. Circulation 2015;131:2176–84. https://doi.org/10.1161/CIRCULATIONAHA.114.014343 doi: 10.1161/CIRCULATIONAHA.114.014343. [DOI] [PubMed]
  78. Schnabel RB, Pecen L, Ojeda FM, Lucerna M, Rzayeva N, Blankenberg S, et al. Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. Heart 2017;103:1024–30. https://doi.org/10.1136/heartjnl-2016-310406 doi: 10.1136/heartjnl-2016-310406. [DOI] [PMC free article] [PubMed]
  79. Berg J, Lindgren P, Nieuwlaat R, Bouin O, Crijns H. Factors determining utility measured with the EQ-5D in patients with atrial fibrillation. Qual Life Res 2010;19:381–90. https://doi.org/10.1007/s11136-010-9591-y doi: 10.1007/s11136-010-9591-y. [DOI] [PubMed]
  80. NHS Business Services. Practice List Size and GP Count for Each Practice. 2018. URL: www.nhsbsa.nhs.uk/prescription-data/organisation-data/practice-list-size-and-gp-count-each-practice (accessed 4 July 2018).
  81. Israel CW, Grönefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 2004;43:47–52. https://doi.org/10.1016/j.jacc.2003.08.027 doi: 10.1016/j.jacc.2003.08.027. [DOI] [PubMed]
  82. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, et al. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 2007;9:1006–23. https://doi.org/10.1093/europace/eum191 doi: 10.1093/europace/eum191. [DOI] [PubMed]
  83. OpenPrescribing beta. Explore England’s Prescribing Data. EBM DataLab University of Oxford. OpenPrescribing.net. 2018. URL: https://openprescribing.net/ (accessed 6 July 2018).
  84. NHS Digital. Practice Level Prescribing in England: A Summary. Leeds: NHS Digital; 2018. URL: https://digital.nhs.uk/data-and-information/areas-of-interest/prescribing/practice-level-prescribing-in-england-a-summary (accessed 12 August 2018).
  85. Sterne JA, Bodalia PN, Bryden PA, Davies PA, López-López JA, Okoli GN, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess 2017;21(9). https://doi.org/10.3310/hta21090 doi: 10.3310/hta21090. [DOI] [PMC free article] [PubMed]
  86. Office for National Statistics. Estimates of the Population for the UK, England and Wales, Scotland and Northern Ireland. Newport: Office for National Statistics; 2018. URL: www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland (accessed June 2018).
  87. Mathisen SM, Dalen I, Larsen JP, Kurz M. Long-term mortality and its risk factors in stroke survivors. J Stroke Cerebrovasc Dis 2016;25:635–41. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.11.039 doi: 10.1016/j.jstrokecerebrovasdis.2015.11.039. [DOI] [PubMed]
  88. Public Health England. First Stroke Estimates in England: 2007 to 2016. London: Public Health England; 2018. URL: www.gov.uk/government/publications/first-stroke-estimates-in-england-2007-to-2016 (accessed 12 August 2018).
  89. NHS Improvement. 2016/17 Reference Costs and Guidance. National Schedule of Reference Costs 2016/17. 2017. URL: https://improvement.nhs.uk/resources/reference-costs/ (accessed 12 August 2018).
  90. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005;366:1773–83. https://doi.org/10.1016/S0140-6736(05)67702-1 doi: 10.1016/S0140-6736(05)67702-1. [DOI] [PubMed]
  91. Mohan KM, Wolfe CD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve AP. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke 2011;42:1489–94. https://doi.org/10.1161/STROKEAHA.110.602615 doi: 10.1161/STROKEAHA.110.602615. [DOI] [PubMed]
  92. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208. https://doi.org/10.1016/0168-8510(90)90421-9 doi: 10.1016/0168-8510(90)90421-9. [DOI] [PubMed]
  93. Robinson A, Thomson R, Parkin D, Sudlow M, Eccles M. How patients with atrial fibrillation value different health outcomes: a standard gamble study. J Health Serv Res Policy 2001;6:92–8. https://doi.org/10.1258/1355819011927288 doi: 10.1258/1355819011927288. [DOI] [PubMed]
  94. Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005;9(40). https://doi.org/10.3310/hta9400 doi: 10.3310/hta9400. [DOI] [PubMed]
  95. Curtis L. Unit Costs of Health and Social Care 2017. Canterbury: PSSRU, University of Kent; 2017.
  96. National Institute for Health and Care Excellence. Routine Preoperative Tests for Elective Surgery (NG45). London: NICE; 2016. URL: www.nice.org.uk/guidance/ng45 (accessed June 2018). [PubMed]
  97. Office for National Statistics. Inflation and Price Indices. Newport: Office for National Statistics; 2017. URL: www.ons.gov.uk/economy/inflationandpriceindices (accessed June 2018).
  98. Department of Health and Social Care. NHS Reference Costs 2016/17. London: Department of Health and Social Care; 2017. URL: https://improvement.nhs.uk/resources/reference-costs/ (accessed 19 March 2018).
  99. National Institute for Health and Care Excellence. Zio Service for Detecting Cardiac Arrhythmias: Medtech Innovation Briefing [MIB101]. London: NICE; 2017. URL: www.nice.org.uk/advice/mib101 (accessed 19 October 2018).
  100. Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. URL: www.medicinescomplete.com (accessed June 2018).
  101. NHS Business Services. NHS Electronic Drug Tariff. 2018. URL: www.drugtariff.nhsbsa.nhs.uk/#/00553921-DA/DA00553911/Part%20VIIIA%20-%20Basic%20Prices%20of%20Drugs (accessed June 2018).
  102. NHS England. Sentinel Stroke National Audit Programme. Cost and Cost-Effectiveness Analysis. 2016. URL: www.strokeaudit.org/SupportFiles/Documents/Health-Economics/Health-economic-report-2016.aspx (accessed 12 August 2018).
  103. Turakhia MP, Shafrin J, Bognar K, Trocio J, Abdulsattar Y, Wiederkehr D, Goldman DP. Estimated prevalence of undiagnosed atrial fibrillation in the United States. PLOS ONE 2018;13:e0195088. https://doi.org/10.1371/journal.pone.0195088 doi: 10.1371/journal.pone.0195088. [DOI] [PMC free article] [PubMed]
  104. Taggar JS, Coleman T, Lewis S, Heneghan C, Jones M. Accuracy of methods for detecting an irregular pulse and suspected atrial fibrillation: A systematic review and meta-analysis. Eur J Prev Cardiol 2016;23:1330–8. https://doi.org/10.1177/2047487315611347 doi: 10.1177/2047487315611347. [DOI] [PMC free article] [PubMed]
  105. Jacobs MS, Kaasenbrood F, Postma MJ, van Hulst M, Tieleman RG. Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. Europace 2018;20:12–18. https://doi.org/10.1093/europace/euw285 doi: 10.1093/europace/euw285. [DOI] [PubMed]
  106. West of England Academic Heath Science Networks. AliveCor Kardia Mobile: NHS England Mobile ECG Device Project. 2018. URL: www.weahsn.net/wp-content/uploads/KardiaAlivecore-Guidance-Document-v-12-BC-DE-UK-15.02.2018.pdf (accessed June 2018).
  107. NHS England. Atrial Fibrillation. 2018. URL: www.england.nhs.uk/mids-east/clinical-networks/east-midlands-clinical-network/our-networks/cardiovascular/atrial-fibrillation/ (accessed August 2018).
  108. McKee S. NHS rolls out KardiaMobile to accelerate detection of arrhythmia. PharmaTimes, 15 February 2018. URL: www.pharmatimes.com/news/nhs_rolls_out_kardiamobile_to_accelerate_detection_of_arrhythmia_1222263 (accessed August 2018).
  109. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014;370:2467–77. https://doi.org/10.1056/NEJMoa1311376 doi: 10.1056/NEJMoa1311376. [DOI] [PubMed]
  110. Sinha AM, Diener HC, Morillo CA, Sanna T, Bernstein RA, Di Lazzaro V, et al. Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale. Am Heart J 2010;160:36–41.e1. https://doi.org/10.1016/j.ahj.2010.03.032 doi: 10.1016/j.ahj.2010.03.032. [DOI] [PubMed]

RESOURCES